Senti Bio Awarded Funding from National Cancer Institute (NCI) to Support Development of Logic Gated Allogeneic CAR-NK Cell Therapy SENTI-202 to Treat Acute Myeloid Leukemia
28. September 2021 08:02 ET
|
Senti Bio
SOUTH SAN FRANCISCO, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Senti Bio, a leading gene circuit company, today announced that it has been awarded a Small Business Innovation Research (SBIR)...
Senti Bio Adds Prominent Scientific and Industry Leaders to its Scientific Advisory Board
17. August 2021 08:00 ET
|
Senti Bio
- Members include world-leading experts in fields of immunotherapy drug discovery and development and commercial oncology therapeutics - - Dr. James Collins, a founder of the field of synthetic...
Senti Bio Signs Lease Agreement and Begins Design of Clinical and Commercial-Scale Manufacturing Facility for Allogeneic CAR-NK Cell Therapies
15. Juni 2021 16:00 ET
|
Senti Bio
- 92,000 square-foot cGMP facility will be designed to support clinical and commercial-scale production of allogeneic CAR-NK cell pipeline - - Facility to initially focus on preclinical product...
Senti Bio and BlueRock Therapeutics Enter Collaboration to Develop Gene Circuit-Engineered Cell Therapies for Regenerative Medicine
26. Mai 2021 08:00 ET
|
Senti Bio; BlueRock Therapeutics LP
CAMBRIDGE, Mass. and SOUTH SAN FRANCISCO, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- BlueRock Therapeutics LP, a leading engineered cell therapy company and a wholly-owned and independently operated...
Senti Bio to Present Data from CAR-NK Cell Oncology Pipeline at ISCT Annual Meeting
25. Mai 2021 08:00 ET
|
Senti Bio
- Senti Bio has designed a scalable process for efficient manufacturing of allogeneic CAR-NK cell pipeline - - Large scale expansion of PBMC-NK cells and UCB-NK cells may provide a scalable source...
Senti Bio Announces Key Leadership Appointments
19. Mai 2021 08:00 ET
|
Senti Bio
- Deborah Knobelman, PhD, appointed Chief Financial Officer - - Curt Herberts, MBS, promoted to Chief Operating Officer and Philip Lee, PhD, promoted to Chief Technology Officer - SOUTH SAN...
Senti Bio to Present Data from CAR-NK Cell Oncology Pipeline at ASGCT 24th Annual Meeting
11. Mai 2021 08:00 ET
|
Senti Bio
- Using Logic Gating gene circuits, Senti Bio is engineering allogeneic CAR-NK cells to target and more precisely eliminate cancer cells while sparing healthy cells - - Using a Regulator Dial...
Senti Bio to Present Data from CAR-NK Cell Oncology Pipeline at Upcoming Scientific Conferences
21. April 2021 16:00 ET
|
Senti Bio
SOUTH SAN FRANCISCO, Calif., April 21, 2021 (GLOBE NEWSWIRE) -- Senti Bio, a leading gene circuit company, today announced the acceptance of five abstracts for presentation at upcoming virtual...
Senti Bio Enters Collaboration with Spark Therapeutics to Develop Next-Generation Precision Gene Therapies
13. April 2021 08:30 ET
|
Senti Bio
- Collaboration combines Senti Bio’s leading-edge gene circuit technology platform and high-throughput synthetic promoter design capabilities with Spark Therapeutics’ investigational gene therapies...
Senti Bio Presents Preclinical Data from CAR-NK Cell Programs at AACR Virtual Annual Meeting
12. April 2021 08:30 ET
|
Senti Bio
SOUTH SAN FRANCISCO, Calif., April 12, 2021 (GLOBE NEWSWIRE) -- Senti Bio, a leading gene circuit company, today announced that results from its discovery-stage oncology program using allogeneic...